Research Article| Volume 29, ISSUE 4, 104605, April 2020

Elevated Cerebrospinal Fluid Protein Is Associated with Unfavorable Functional Outcome in Spontaneous Subarachnoid Hemorrhage


      Background/objective: Subarachnoid hemorrhage (SAH) is a devastating neurologic event for which markers to assess poor outcome are needed. Elevated cerebrospinal fluid (CSF) protein may result from inflammation and blood-brain barrier (BBB) disruption that occurs during SAH. We sought to determine if CSF protein level is associated with functional outcome after SAH. Methods: We prospectively collected single-center demographic and clinical data for consecutive patients admitted with spontaneous SAH. Inclusion required an external ventricular drain and daily CSF protein and cellular counts starting within 48 hours of symptom onset and extending through 7 days after onset. Seven-day average CSF protein was determined from daily measured values after correcting for contemporaneous CSF red blood cell (RBC) count. Three-month functional outcome was assessed by telephone interview with good outcome defined as modified Rankin score 0-3. Variables univariately associated with outcome at P less than .25 and measures of hemorrhage volume were included for binary logistic regression model development. Results: The study included 130 patients (88% aneurysmal SAH, 69% female, 54.8 ± 14.8 years, Glasgow Coma Scale [GCS] 14 [7-15]). Three-month outcome assessment was complete in 112 (86%) patients with good functional outcome in 74 (66%). CSF protein was lower in good outcome (35.3 [20.4-49.7] versus 80.5 [40.5-115.5] mg/dL; P < .001). CSF protein was not associated with cerebral vasospasm, but delayed radiographic infarction on 3 to 12-month neuroimaging was associated with higher CSF protein (46.3 [32.0-75.0] versus 30.2 [20.4-47.8] mg/dL; P = .023). Good 3-month outcome was independently associated with lower CSF protein (odds ratios [OR] .39 [.23-.70] for 75th versus 25th percentile of protein; P = .001) and higher admission GCS (OR 1.23 [1.10-1.37] for good outcome per GCS point increase; P < .001). Parenchymal hematoma predicted worse outcome (OR 6.31 [1.58-25.25]; P = .009). Results were similar after excluding nonaneurysmal SAH and after including CSF RBC count, CT score, and intraventricular hemorrhage volume in models. Conclusions: Elevated average CSF protein is associated with poor outcome after spontaneous SAH. Further research should investigate if elevated CSF protein identifies patients in whom mechanisms such as BBB disruption contribute to poor outcome.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Johnston S.C.
        • Selvin S.
        • Gress D.R.
        The burden, trends, and demographics of mortality from subarachnoid hemorrhage.
        Neurology. 1998; 50: 1413-1418
        • Macdonald R.L.
        • Higashida R.T.
        • Keller E.
        • et al.
        Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.
        Stroke. 2012; 43: 1463-1469
        • Chen S.
        • Feng H.
        • Sherchan P.
        • et al.
        Controversies and evolving new mechanisms in subarachnoid hemorrhage.
        Prog Neurobiol. 2014; 115: 64-91
        • Killingsworth L.M.
        Clinical applications of protein determinations in biological fluids other than blood.
        Clin Chem. 1982; 28: 1093-1102
        • Liotta E.M.
        • Prabhakaran S.
        • Sangha R.S.
        • et al.
        Magnesium, hemostasis, and outcomes in patients with intracerebral hemorrhage.
        Neurology. 2017; 89: 813-819
        • Seehusen D.A.
        • Reeves M.M.
        • Fomin D.A.
        Cerebrospinal fluid analysis.
        Am Fam Physician. 2003; 68: 1103-1108
        • Banks J.L.
        • Marotta C.A.
        Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis.
        Stroke. 2007; 38: 1091-1096
        • Wilson J.T.
        • Hareendran A.
        • Grant M.
        • et al.
        Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale.
        Stroke. 2002; 33: 2243-2246
        • Young-Saver D.F.
        • Gornbein J.
        • Starkman S.
        • et al.
        Handling of missing outcome data in acute stroke trials: advantages of multiple imputation using baseline and postbaseline variables.
        J Stroke Cerebrovasc Dis. 2018; 27: 3662-3669
        • Barker 2nd, F.G.
        • Ogilvy C.S.
        Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis.
        J Neurosurg. 1996; 84: 405-414
        • Feigin V.L.
        • Rinkel G.J.
        • Algra A.
        • et al.
        Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review.
        Neurology. 1998; 50: 876-883
        • Dorhout Mees S.M.
        • Rinkel G.J.
        • Feigin V.L.
        • et al.
        Calcium antagonists for aneurysmal subarachnoid haemorrhage.
        Cochrane Database Syst Rev. 2007; CD000277
        • Shen J.
        • Pan J.W.
        • Fan Z.X.
        • et al.
        Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
        J Neurosurg. 2013; 119: 180-189
        • Tam A.K.
        • Kapadia A.
        • Ilodigwe D.
        • et al.
        Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage.
        J Neurosurg. 2013; 119: 198-206
        • Friedrich V.
        • Flores R.
        • Sehba F.A.
        Cell death starts early after subarachnoid hemorrhage.
        Neurosci Lett. 2012; 512: 6-11
        • Doczi T.
        • Joo F.
        • Adam G.
        • et al.
        Blood-brain barrier damage during the acute stage of subarachnoid hemorrhage, as exemplified by a new animal model.
        Neurosurgery. 1986; 18: 733-739
        • Johshita H.
        • Kassell N.F.
        • Sasaki T.
        Blood-brain barrier disturbance following subarachnoid hemorrhage in rabbits.
        Stroke. 1990; 21: 1051-1058
        • Anzabi M.
        • Ardalan M.
        • Iversen N.K.
        • et al.
        Hippocampal atrophy following subarachnoid hemorrhage correlates with disruption of astrocyte morphology and capillary coverage by AQP4.
        Front Cell Neurosci. 2018; 12: 19
        • Ivanidze J.
        • Kesavabhotla K.
        • Kallas O.N.
        • et al.
        Evaluating blood-brain barrier permeability in delayed cerebral infarction after aneurysmal subarachnoid hemorrhage.
        AJNR Am J Neuroradiol. 2015; 36: 850-854
        • Ivanidze J.
        • Ferraro R.A.
        • Giambrone A.E.
        • et al.
        Blood-brain barrier permeability in aneurysmal subarachnoid hemorrhage: correlation with clinical outcomes.
        AJR Am J Roentgenol. 2018; 211: 891-895
        • Russin J.J.
        • Montagne A.
        • D'Amore F.
        • et al.
        Permeability imaging as a predictor of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
        J Cereb Blood Flow Metab. 2018; 38: 973-979
        • Mathiesen T.
        • Edner G.
        • Ulfarsson E.
        • et al.
        Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage.
        J Neurosurg. 1997; 87: 215-220
        • Muroi C.
        • Hugelshofer M.
        • Seule M.
        • et al.
        Correlation among systemic inflammatory parameter, occurrence of delayed neurological deficits, and outcome after aneurysmal subarachnoid hemorrhage.
        Neurosurgery. 2013; 72: 367-375
        • Nakahara T.
        • Tsuruta R.
        • Kaneko T.
        • et al.
        High-mobility group box 1 protein in CSF of patients with subarachnoid hemorrhage.
        Neurocrit Care. 2009; 11: 362-368
        • Lucke-Wold B.P.
        • Logsdon A.F.
        • Manoranjan B.
        • et al.
        Aneurysmal subarachnoid hemorrhage and neuroinflammation: a comprehensive review.
        Int J Mol Sci. 2016; 17: 497
        • Sokol B.
        • Wasik N.
        • Wieckowska B.
        • et al.
        Predicting mortality in subarachnoid haemorrhage based on first-week routine blood tests.
        J Clin Neurosci. 2018; 58: 100-107
        • Cahill J.
        • Calvert J.W.
        • Zhang J.H.
        Mechanisms of early brain injury after subarachnoid hemorrhage.
        J Cereb Blood Flow Metab. 2006; 26: 1341-1353
        • Kooijman E.
        • Nijboer C.H.
        • van Velthoven C.T.
        • et al.
        Long-term functional consequences and ongoing cerebral inflammation after subarachnoid hemorrhage in the rat.
        PLoS One. 2014; 9: e90584
        • Prunell G.F.
        • Svendgaard N.A.
        • Alkass K.
        • et al.
        Inflammation in the brain after experimental subarachnoid hemorrhage.
        Neurosurgery. 2005; 56 (discussion 1082-1092): 1082-1092